Get the Stockscreener App
5.92
8.78%
-0.57
After Hours:
6.02
0.10
+1.69%
Helus Pharma Inc stock is traded at $5.92, with a volume of 465.41K.
It is down -8.78% in the last 24 hours and down -19.78% over the past month.
Helus Pharma Inc is a clinical-stage pharmaceutical company developing proprietary novel serotonergic agonists (NSAs), which are synthetic molecules designed to activate serotonin pathways associated with neuroplasticity. These compounds are being investigated for potential use in the treatment of depression, anxiety, and other mental health conditions, areas where there is an unmet medical need. It aims to provide treatments designed for mental health disorders. The company is currently developing HLP003, a proprietary NSA, in Phase 3 clinical development for the adjunctive treatment of substantial depressive disorder. It operates in Canada, the United States, the United Kingdom, and Ireland.
See More
Previous Close:
$6.49
Open:
$6.56
24h Volume:
465.41K
Relative Volume:
2.44
Market Cap:
$295.37M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
+1.02%
1M Performance:
-19.78%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$5.88
$6.65
1-Week Range:
$5.76
$7.19
52-Week Range:
$5.76
$8.23
Helus Pharma Inc Stock (HELP) Company Profile
Compare HELP vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
HELP
Helus Pharma Inc
|
5.92 | 323.81M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Helus Pharma Inc Stock (HELP) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-02-26 | Initiated | Jefferies | Buy |
| Mar-13-25 | Initiated | Guggenheim | Buy |
| Nov-19-21 | Downgrade | Maxim Group | Buy → Hold |
Helus Pharma Inc Stock (HELP) Latest News
Helus Pharma appoints Michael Cola as CEO - The Pharma Letter
Helus Pharma Names Michael Cola As CEO For Next Phase Of Growth - bernama
Helus Pharma appoints Michael Cola as CEO amid clinical trial milestones By Investing.com - Investing.com South Africa
Helus Pharma Appoints Michael Cola as Chief Executive Officer to Lead Next Phase of Scale and Execution - wahanariau.com
Helus Pharma Appoints Michael Cola as Chief Executive Officer, Effective February 10, 2026 - marketscreener.com
Taking the Helm at Helus: A Brief Q&A With New CEO Michael Cola - Psychedelic Alpha
Novel Serotonergic Agonists Positioned to Capture Share of $150B+ Neuropsychiatric Market - Newswire Canada
Helus Pharma appoints Michael Cola as CEO amid clinical trial milestones - Investing.com Canada
Helus Pharma Appoints Michael Cola as Chief Executive Officer to Lead Next Phase of Scale and ... - Caledonian Record
Will Helus Pharma's GAD Trial Data Calm Investor Anxiety? - RTTNews
Jefferies initiates Helus Pharma stock with Buy rating on upcoming catalysts - Investing.com Canada
Jefferies initiates Helus Pharma stock with Buy rating on upcoming catalysts By Investing.com - Investing.com South Africa
Pα+ Psychedelic Bulletin #217: Gilgamesh’s GM-1020 Prints Positive Topline; FDA Lifts Hold on GH Research’s 5-MeO-DMT IND; Compass Details Pivotal PTSD Trial Design; Cybin Becomes Helus - Psychedelic Alpha
Breakthrough or Bubble? The High-Stakes 2026 Readouts for Psychedelic Giants - geneonline.com
Psychedelic Funding, Public Markets, and M&A in 2025 - Psychedelic Alpha
The Psychedelic News Feed: January 1218, 2026 - Psychedelic Alpha
Definium points the way forward as MindMed drops old identity - Fierce Pharma
The Psychedelic News Feed: January 0511, 2026 - Psychedelic Alpha
Why Cybin (HELP) Is Down 9.1% After Rebranding To Helus And Relisting On Nasdaq - Yahoo Finance
Assessing Cybin’s Valuation As Helus Pharma Uplists To Nasdaq And Joins The Nasdaq Composite Index - Sahm
Helus Pharma Rings the Opening Bell - Nasdaq
HELUS Pharma Propels Therapeutic Innovation in Mental Health and Commences Trading on Nasdaq - bernama
Helus Pharma Rebrands, Debuts On Nasdaq - bernama
Cybin (CYBN) Is Down 9.8% After Launching US$100M At-The-Market Equity ProgramWhat's Changed - simplywall.st
HELUS PHARMA REBRANDS, DEBUTS ON NASDAQ - bernama
Cybin (CYBN) Transitions to Helus Pharma and Moves to Nasdaq - GuruFocus
Cybin to Begin Nasdaq Trading Under New Ticker, Plans to Change Name to Helus Pharma - marketscreener.com
Helus Pharma Rebrands, Moves to Nasdaq as It Advances Late-Stage Mental Health Drugs - TipRanks
Cybin launches $100 million at-the-market equity program By Investing.com - Investing.com Australia
The New Psychedelics: One Dose, Eight Hours, a Therapist on Standby - Bloomberg.com
Cybin (CYBN) Receives a Buy from H.C. Wainwright - The Globe and Mail
Cybin to Rebrand as Helus Pharma and Shift U.S. Listing to Nasdaq in Early January - TipRanks
Cybin to rebrand as Helus Pharma and shift US listing to Nasdaq - MSN
Cybin to Rebrand as Helus Pharma and Shift U.S. Listing to Nasdaq - TipRanks
Cybin to Transfer U.S. Stock Exchange Listing to Nasdaq - Business Wire
Cybin to transfer listing from NYSE American to Nasdaq, rebrand - Investing.com
Cybin Reports Second Quarter Fiscal Year 2026 Financial Results and Recent Business Highlights - Business Wire
Cybin to Participate in the Jefferies Global Healthcare Conference in London - Business Wire
Cybin to Announce Second Quarter Financial Results and Provide Business Update on November 13, 2025 - Business Wire
Cybin to Participate at the 2025 Milken Institute Future of Health Summit - Business Wire
Finance Watch: MapLight Brings US Biopharma IPO Tally To 11 In 2025 - Citeline News & Insights
Cybin announces $175 million registered direct offering - marketscreener.com
Cybin Announces $175 Million Registered Direct Offering - Business Wire
Cybin Stock: Optimism Quickly Fades (NYSE:CYBN) - Seeking Alpha
Cybin Highlights Neuropsychiatry Platform and Upcoming Clinical Milestones - Business Wire
Cybin Completes Enrollment in Phase 2 Study Evaluating CYB004 for the Treatment of Generalized Anxiety Disorder - Business Wire
Cybin to Participate in the H.C. Wainwright 27th Annual Global Investment Conference - Business Wire
Cybin to Participate in the Cantor Global Healthcare Conference 2025 - Business Wire
Cybin Announces Senior Leadership Changes - Business Wire
Cybin Receives Australian Approval for EMBRACE, a Multinational Pivotal Study Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder - Business Wire
Cybin Receives European Approval for EMBRACE, a Multinational Phase 3 Study Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder - Business Wire
Helus Pharma Inc Stock (HELP) Financials Data
There is no financial data for Helus Pharma Inc (HELP). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
1.24%
0.19%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):